Wu Bin Pan is the founder of Crown Bioscience International, founded in 2006. He was also the founder of Crown Bioscience, Inc., founded in 2006, where he held the title of Chief Operating Officer, EVP & China President from 2006 to 2011. In 2012, Dr. Pan founded Suzhou Connect Biopharma Co. Ltd., where he currently serves as Chairman & President. He also founded Connect Biopharma Holdings Ltd. in 2012 and holds the title of Director. Dr. Pan's current job is as a Director at Connect Biopharma HongKong Ltd. He previously worked as a Principal at Terragen Discovery, Inc. and as Vice President at Shenzhen Yuanxing Biomedical Technology Co., Ltd. from 2000 to 2006. Dr. Pan's education includes a doctorate from the University of Sussex in 1994, an MBA from Tsinghua University in 2010, and an undergraduate degree from Sun Yat-Sen University in 1985.
Zheng Wei
Zheng Wei is the founder of Connect Biopharma Holdings Ltd., which was founded in 2015. He is currently the Chief Executive Officer & Director at Connect Biopharm LLC. Dr. Wei previously worked as the Director-Immunology at Arena Pharmaceuticals, Inc. from 2007 to 2011. He holds a doctorate degree from the University of California, Davis, and an undergraduate degree from South China Normal University.
Wu Bin Pan
Wu Bin Pan is the founder of Crown Bioscience International, founded in 2006. He was also the founder of Crown Bioscience, Inc., founded in 2006, where he held the title of Chief Operating Officer, EVP & China President from 2006 to 2011. In 2012, Dr. Pan founded Suzhou Connect Biopharma Co. Ltd., where he currently serves as Chairman & President. He also founded Connect Biopharma Holdings Ltd. in 2012 and holds the title of Director. Dr. Pan's current job is as a Director at Connect Biopharma HongKong Ltd. He previously worked as a Principal at Terragen Discovery, Inc. and as Vice President at Shenzhen Yuanxing Biomedical Technology Co., Ltd. from 2000 to 2006. Dr. Pan's education includes a doctorate from the University of Sussex in 1994, an MBA from Tsinghua University in 2010, and an undergraduate degree from Sun Yat-Sen University in 1985.
Karen J. Wilson
Karen J. Wilson founded GV Partners LLC in 2004, where she worked as CEO from 2004 to 2007. Ms. Wilson also currently works at Elicio Therapeutics, Inc. (United States), as Director, LAVA Therapeutics NV, as Independent Non-Executive Director from 2021, Suzhou Connect Biopharma Co. Ltd., as Director from 2020, and various other companies. Ms. Wilson also formerly worked at The World Economic Forum USA, Inc., as Executive Director & Associate Member of the Board from 1999 to 2001, Index Venture Management (US), Inc., as Director from 2001 to 2004, Harvard Business School, as Executive Director & Global Initiative from 1993 to 1999, and various other companies. Ms. Wilson received her undergraduate degree in 1986 from the University of California, Berkeley and Masters Business Admin degree from Harvard Business School.
Kleanthis G. Xanthopoulos
Kleanthis G. Xanthopoulos was the founder of Anadys Pharmaceuticals, Inc., founded in 1992, where the title held was Director from 2006 to 2011. Dr. Xanthopoulos is the founder of Senté, Inc., founded in 2007, holding the title of Executive Chairman starting in 2026. Dr. Xanthopoulos is the founder of SENTé Labs, founded in 2007, holding the title of Director. Dr. Xanthopoulos is also the founder of Shoreline Biosciences, Inc... Current jobs include Chairman at Stork Capital SARL since 2020, Chairman at Connect Biopharma Holdings Ltd. since 2024, Director at Irras AB since 2021, Director at Suzhou Connect Biopharma Co. Ltd. since 2020, President at Helios, Inc., and Managing Partner at Vandel Group LLC. Former jobs include President, Chief Executive Officer & Director at Regulus Therapeutics, Inc. in 2015; Chairman at Apricus Biosciences, Inc. from 2013 to 2019; Chairman at Bioniz Therapeutics, Inc. in 2016; Director at ZP Opco, Inc.; Director at Biotechnology Innovation Organization; Director at J.E.M. Capital, Inc. from 2013 to 2014; Managing Director at Enterprise Partners Venture Capital in 2007; Director at Odyssey Thera, Inc.; Director at Aspirus, Inc.; Director at Laboratori Derivati Organici SpA from 2016 to 2017; Independent Director at Zosano Pharma Corp. from 2013 to 2021; Executive Director at Biocom, Inc. in 2014; Senior Vice President at Ionis Pharmaceuticals, Inc.; Vice President-Genomics & Molecular Biology at Aurora Biosciences Corp. from 1997 to 2000; Associate Professor at Karolinska Institutet; Section Head at National Human Genome Research Institute from 1995 to 1997; Managing General Partner at Cerus Advisors DMCC from 2015 to 2020. Education includes a doctorate conferred in 1986 and a graduate degree conferred in 1982 from the University of Stockholm, and an undergraduate degree conferred in 1980 from Aristotle University of Thessaloniki.
Kleanthis G. Xanthopoulos
Kleanthis G. Xanthopoulos was the founder of Anadys Pharmaceuticals, Inc., founded in 1992, where the title held was Director from 2006 to 2011. Dr. Xanthopoulos is the founder of Senté, Inc., founded in 2007, holding the title of Executive Chairman starting in 2026. Dr. Xanthopoulos is the founder of SENTé Labs, founded in 2007, holding the title of Director. Dr. Xanthopoulos is also the founder of Shoreline Biosciences, Inc... Current jobs include Chairman at Stork Capital SARL since 2020, Chairman at Connect Biopharma Holdings Ltd. since 2024, Director at Irras AB since 2021, Director at Suzhou Connect Biopharma Co. Ltd. since 2020, President at Helios, Inc., and Managing Partner at Vandel Group LLC. Former jobs include President, Chief Executive Officer & Director at Regulus Therapeutics, Inc. in 2015; Chairman at Apricus Biosciences, Inc. from 2013 to 2019; Chairman at Bioniz Therapeutics, Inc. in 2016; Director at ZP Opco, Inc.; Director at Biotechnology Innovation Organization; Director at J.E.M. Capital, Inc. from 2013 to 2014; Managing Director at Enterprise Partners Venture Capital in 2007; Director at Odyssey Thera, Inc.; Director at Aspirus, Inc.; Director at Laboratori Derivati Organici SpA from 2016 to 2017; Independent Director at Zosano Pharma Corp. from 2013 to 2021; Executive Director at Biocom, Inc. in 2014; Senior Vice President at Ionis Pharmaceuticals, Inc.; Vice President-Genomics & Molecular Biology at Aurora Biosciences Corp. from 1997 to 2000; Associate Professor at Karolinska Institutet; Section Head at National Human Genome Research Institute from 1995 to 1997; Managing General Partner at Cerus Advisors DMCC from 2015 to 2020. Education includes a doctorate conferred in 1986 and a graduate degree conferred in 1982 from the University of Stockholm, and an undergraduate degree conferred in 1980 from Aristotle University of Thessaloniki.
Jean I. Liu
Currently, Jean I. Liu is Director at Suzhou Connect Biopharma Co. Ltd., Independent Director at Erasca, Inc. since 2022, Independent Director at Connect Biopharma Holdings Ltd. since 2021, and Member of The State Bar of California. Formerly, Ms. Liu was Director at Cascadian Therapeutics LLC; Secretary, Senior Vice President & General Counsel at DURECT Corp. from 1998 to 2011; Secretary & Chief Legal Officer at Seagen, Inc. from 2021 to 2023; Secretary, Vice President & General Counsel at Halozyme Therapeutics, Inc. from 2012 to 2014; Attorney at Pillsbury Madison & Sutro LLP from 1993 to 1997; and Attorney at Venture Law Group from 1997 to 1998. Education includes graduate degrees from The Trustees of Columbia University in The City of New York and Stanford University, and an undergraduate degree from the University of Michigan.
Zuie Chin Huang
Zuie Chin Huang founded Orion Biotech Opportunities Corp. in 2021, where he is working as Chief Executive Officer & Director from 2021. Mr. Huang also founded Zai Lab Ltd., Legend Biotech Corp., and TriArm Therapeutics (Taiwan) Ltd., where he is working as Chairman. Mr. Huang also currently works at Wuhan Kindstar Co. Ltd., as Chairman, Eden Biologics, Inc., as Co-Chairman, Tactiva Therapeutics LLC, as Chairman, and various other companies. Mr. Huang also formerly worked at Windtree Therapeutics, Inc., as Chairman from 2019 to 2023, Alaunos Therapeutics, Inc., as Executive Chairman from 2021 to 2023, Ceptaris Therapeutics, Inc., as Director, and various other companies. Mr. Huang received his graduate degree from Stanford University, undergraduate degree in 1988 from the University of California, Berkeley, and Masters Business Admin degree in 1992 from Stanford Graduate School of Business.
Barry D. Quart
Barry D. Quart was the founder of Ardea Biosciences, Inc., founded in 2006, where the titles held included President, Chief Executive Officer & Director from 2012 to 2013. Current jobs include Chief Executive Officer & Director at Connect Biopharma Holdings Ltd. starting in 2024; Director at NeuroGenetic Pharmaceuticals, Inc.; Independent Director at Kiniksa Pharmaceuticals Ltd. since 2015; Director at Kiniksa Pharmaceuticals Corp.; and Independent Director at Kiniksa Pharmaceuticals International Plc starting in 2024. Former jobs include Chairman & Chief Executive Officer at Heron Therapeutics, Inc. from 2020 to 2023; Director at Trimeris, Inc. from 2007 to 2011; Director, SVP-Global Research & Development at Pfizer (La Jolla); Independent Director at Synageva BioPharma Corp. from 2012 to 2015; President-Research & Development at Agouron Pharmaceuticals LLC; Senior VP-Pfizer Global Research & Development at Pfizer Inc.; and President at Napo Pharmaceuticals, Inc. from 2002 to 2006. Education includes a doctorate from The University of California, San Francisco.
James A. Schoeneck
James A. Schoeneck is Chairman at Kyntra Bio, Inc. since 2020. Mr. Schoeneck is Chairman at Calidi Biotherapeutics, Inc. starting in 2025. Mr. Schoeneck is Independent Director at Connect Biopharma Holdings Ltd. starting in 2025. Mr. Schoeneck is Director at Calidi Biotherapeutics (Nevada), Inc. since 2020. Formerly, Mr. Schoeneck was President, Chief Executive Officer & Director at Assertio Therapeutics, Inc. from 2011 to 2017. Mr. Schoeneck was Chief Executive Officer at BrainCells, Inc. from 2005 to 2011. Mr. Schoeneck was Chief Executive Officer at ActivX Biosciences, Inc. from 2003 to 2004. Mr. Schoeneck was Director at AnaptysBio, Inc. from 2015 to 2018. Mr. Schoeneck was Director-Marketing & Product Group at Rhone-Poulenc Rorer, Inc. Mr. Schoeneck was Vice President & General Manager-Immunology at Centocor, Inc. from 1996 to 1999. Mr. Schoeneck was Principal at KYORIN Pharmaceutical Co. Ltd. (old). Mr. Schoeneck was President, Chief Executive & Operating Officer at Prometheus Laboratories, Inc. from 1999 to 2003. Mr. Schoeneck completed undergraduate education at Jacksonville State University in 1979.
提供，免责声明：天汇财经、Factset及其他信息供应商努力确保所提供信息的准确性和可靠性，但对于其正确性或可靠性则不予担保，且对于因不正确或疏漏所造成的任何损失或损坏概不负责(无论是有关民事过失、合同或其他方面)。